(IN BRIEF) Novartis has reported positive interim results from its Phase III ALIGN study involving atrasentan, an oral endothelin A receptor antagonist, for the treatment of IgA nephropathy (IgAN). The study demonstrated that atrasentan significantly reduced proteinuria (excess protein in urine) compared to a placebo in IgAN patients receiving supportive care. This marks a crucial development as IgAN is a leading cause of kidney disease and failure. Novartis plans to seek accelerated approval for atrasentan in the United States based on these results. The study is ongoing to evaluate kidney function, with final results expected in early 2026.
(PRESS RELEASE) BASEL, 30-Oct-2022 — /EuropaWire/ — Novartis (SWX: NOVN), a Swiss multinational pharmaceutical company, today unveiled promising topline results from the interim analysis of the pivotal Phase III ALIGN study (NCT04573478) investigating atrasentan, an oral endothelin A receptor antagonist (ERA), in patients grappling with IgA nephropathy (IgAN)¹. At the 36-week interim analysis, the study successfully achieved its primary efficacy endpoint, demonstrating that atrasentan exhibited superiority over placebo. It showcased a clinically meaningful and highly statistically significant reduction in proteinuria (presence of excess protein in urine) among IgAN patients receiving supportive care, characterized by the maximally tolerated and stable dose of a renin-angiotensin system (RAS) inhibitor¹. The safety profile of atrasentan in this study remained consistent with previously reported data from the Phase II AFFINITY study’s IgAN cohort1,2–4. Encouraged by these interim findings on proteinuria, Novartis intends to submit an application for possible accelerated approval in the US in 2024.
“These positive topline Phase III data showcase the potential of atrasentan to improve outcomes for patients with IgAN by demonstrating clinically meaningful proteinuria reduction,” said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer, Novartis. “Along with investigational iptacopan, which recently also showed positive topline Phase III results, and investigational zigakibart, our development portfolio of three highly differentiated late-stage therapies in IgAN has the potential to provide much-needed treatment options for people living with this debilitating disease.”
IgA nephropathy is a prominent contributor to chronic kidney disease and kidney failure, predominantly affecting young adults5. Disturbingly, up to 30% of individuals with IgAN who exhibit persistent high levels of proteinuria (≥1 g/day) are at risk of progressing to kidney failure within a decade6. Consequently, there is a pressing need for efficacious therapies in IgAN that can effectively slow down the progression to kidney failure5,7,8.
Atrasentan, an investigational oral endothelin A receptor antagonist, currently in development for IgAN and other rare kidney diseases, became part of Novartis’ portfolio following the recent acquisition of Chinook Therapeutics. This acquisition also included zigakibart (BION-1301), an investigational subcutaneously administered anti-APRIL monoclonal antibody in Phase III development for IgAN9. These additions, along with an early-stage pipeline, bolster Novartis’ renal portfolio, which already includes iptacopan, an investigational factor B inhibitor that recently reported positive Phase III interim results in IgAN10. Novartis is diligently advancing the development of these three potential therapeutic options, each with distinct mechanisms of action, to address unmet needs not only in IgAN but also in other rare kidney diseases.
The ALIGN study remains ongoing in a blinded fashion, focusing on evaluating changes in kidney function over 136 weeks, as measured by estimated glomerular filtration rate (eGFR). Topline results from the confirmatory endpoint analysis are anticipated in the first quarter of 202611,12.
About the study
The ALIGN study (NCT04573478) is a global, randomized, multicenter, double-blind, placebo-controlled Phase III clinical trial comparing the efficacy and safety of atrasentan versus placebo in patients with IgAN at risk of progressive loss of kidney function11,12. Approximately 340 patients with biopsy-proven IgAN with baseline total proteinuria over one gram per day despite optimized RAS inhibitor treatment were randomized to receive once-daily oral doses of atrasentan (0.75 mg) or placebo for approximately 2.5 years (132 weeks)11,12. Patients continue receiving a maximally tolerated and stable dose of a RAS (renin-angiotensin system) inhibitor as supportive care (unless they are unable to tolerate RAS inhibitor therapy)11,12. An additional group of up to 64 patients receiving a stable dose of SGLT2 inhibitor for at least 12 weeks have also been enrolled11,12.
The primary efficacy endpoint of the study is change in proteinuria as measured by urine protein to creatinine ratio (UPCR) from baseline to 36 weeks11,12. Secondary and exploratory objectives include evaluating the change in kidney function from baseline to week 136 as measured by eGFR, as well as safety and tolerability11,12. Topline results from the confirmatory endpoint analysis are expected in the first quarter of 202611,12.
About atrasentan
Atrasentan is an investigational oral endothelin A receptor antagonist (ERA), currently in Phase III development for IgAN and early-stage development for other rare kidney diseases2–4,9,11,12. Atrasentan has shown significant reductions in proteinuria versus baseline in a Phase II trial for IgAN2-4.
About IgA nephropathy (IgAN)
IgAN is a progressive, rare kidney disease that mostly affects young adults5. It is estimated that approximately 110,000 people in the US and 47,000 people across 10 European countries live with IgAN, with approximately 25 people per million newly diagnosed with IgAN each year globally5,13–16.
In IgAN, autoimmune reaction to an abnormal form of IgA results in formation of immune complexes that deposit in the kidney5,7,17–19. These immune complexes trigger an inflammatory response leading to progressive kidney damage and loss of kidney function5,7,17–19. Up to 30% of people who have IgAN with persistent higher levels of proteinuria (≥1 g/day) progress to kidney failure within 10 years6.
There is a need for effective therapies for IgAN that can help slow progression to kidney failure5,7,8.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “plans,” “accelerated,” “continues,” “advancing,” “potential,” “to address,” “ongoing,” “to submit,” “transform,” “investigational,” “advancing,” “will,” to evaluate,” “can,” “expected,” “progressive,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for atrasentan or the other investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that atrasentan or the other investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding atrasentan or the other investigational or approved products described in this press release could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.
References
- Novartis data on file.
- Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022. Chinook Therapeutics, Inc. Accessed October 18, 2023. https://investors.chinooktx.com/news-releases/news-release-details/chinook-therapeutics-presents-updated-data-atrasentan-phase-2
- Kim SG, Akinfolarin AA, Inker LA, et al. WCN23-1117 ATRASENTAN IN PATIENTS WITH PROTEINURIC GLOMERULAR DISEASES – THE AFFINITY STUDY. Kidney Int Rep. 2023;8(9):1902. doi:10.1016/j.ekir.2023.02.1089.
- Kim SG, Inker LA, Packham DK, et al. WCN23-1126 ATRASENTAN FOR THE TREATMENT OF IGA NEPHROPATHY: INTERIM RESULTS OF THE AFFINITY STUDY. Kidney Int Rep. 2023;8(9):1902. doi:10.1016/j.ekir.2023.02.1088.
- Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1-S276. doi:10.1016/j.kint.2021.05.021.
- Reich HN, Troyanov SAA, Scholey JW, Cattran DC. Remission of Proteinuria Improves Prognosis in IgA Nephropathy. J Am Soc Nephrol. 2007;18(12):3177-3183. doi:10.1681/ASN.2007050526.
- Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 2012;81(9):833-843. doi:10.1038/ki.2011.501.
- Xie J, Kiryluk K, Wang W, et al. Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score. Moura IC, ed. PLoS ONE. 2012;7(6):e38904. doi:10.1371/journal.pone.0038904.
- Novartis completes acquisition of Chinook Therapeutics. Novartis. Accessed October 18, 2023. https://www.novartis.com/news/media-releases/novartis-completes-acquisition-chinook-therapeutics
- Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN). Novartis. Accessed October 18, 2023. https://www.novartis.com/news/media-releases/novartis-investigational-iptacopan-phase-iii-study-demonstrates-clinically-meaningful-and-highly-statistically-significant-proteinuria-reduction-patients-iga-nephropathy-igan
- ClinicalTrials.gov. Atrasentan in Patients With IgA Nephropathy (ALIGN). NCT04573478. Accessed October 18, 2023. https://clinicaltrials.gov/study/NCT04573478
- Lambers Heerspink H, Jardine M, Kohan DE, et al. WCN23-1085 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATY- THE ALIGN STUDY. Kidney Int Rep. 2023;8(3):S279-S280. doi:10.1016/j.ekir.2023.02.630.
- McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414-430. doi:10.1093/ndt/gfq665.
- Lerma EV, Bensink ME, Thakker KM, et al. Impact of Proteinuria and Kidney Function Decline on Health Care Costs and Resource Utilization in Adults With IgA Nephropathy in the United States: A Retrospective Analysis. Kidney Med. 2023;5(9). doi:10.1016/j.xkme.2023.100693.
- U.S. Census Bureau. QuickFacts: United States. Accessed October 26, 2023. https://www.census.gov/quickfacts/fact/table/US/PST045222
- Willey CJ, Coppo R, Schaefer F, Mizerska-Wasiak M, Mathur M, Schultz MJ. The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial Transplant. 2023;38(10):2340-2349. doi:10.1093/ndt/gfad082.
- Lafayette RA, Kelepouris E. Immunoglobulin A Nephropathy: Advances in Understanding of Pathogenesis and Treatment. Am J Nephrol. 2018;47(Suppl. 1):43-52. doi:10.1159/000481636.
- Lai KN, Tang SCW, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primer. 2016;2(1):16001. doi:10.1038/nrdp.2016.1.
- Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677-686. doi:10.2215/CJN.07420716.
# # #
Media contacts:
Novartis Media Relations | |||||
Central | North America | ||||
Richard Jarvis | +41 79 584 2326 | Julie Masow | +1 862 579 8456 | ||
Anja von Treskow | +41 79 392 9697 | Michael Meo | +1 862 274 5414 | ||
Switzerland | +41 79 619 2035 | ||||
Novartis Investor Relations | |||||
Central | North America | ||||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 345 4440 | ||
Nicole Zinsli-Somm | +41 61 324 3809 | Parag Mahanti | +1 973 876 4912 | ||
Isabella Zinck | +41 61 324 7188 | Jonathan Graham | +1 201 602 9921 | ||
Imke Kappes | +41 61 324 8269 | ||||
Zain Iqbal | +41 61 324 0390 |
SOURCE: Novartis
- HTR makes available engineering models of full-metal elastic Lunar wheels
- Tribunal de EE.UU. advierte a Ricardo Salinas: cumpla o enfrentará multas y cárcel por desacatoo
- Digi Communications N.V. announces corporate restructuring of Digi Group’s affiliated companies in Belgium
- Aortic Aneurysms: EU-funded Pandora Project Brings In-Silico Modelling to Aid Surgeons
- BREAKING NEWS: New Podcast “Spreading the Good BUZZ” Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives Through Hope and Community in Recovery
- Cha Cha Cha kohtub krüptomaailmaga: Winz.io teeb koostööd Euroopa visionääri ja staari Käärijäga
- Digi Communications N.V. announces Conditional stock options granted to Executive Directors of the Company, for the year 2025, based on the general shareholders’ meeting approval from 25 June 20244
- Cha Cha Cha meets crypto: Winz.io partners with European visionary star Käärijä
- Digi Communications N.V. announces the exercise of conditional share options by the executive directors of the Company, for the year 2024, as approved by the Company’s OGSM from 25 June 2024
- “Su Fortuna Se Ha Construido A Base de La Defraudación Fiscal”: Críticas Resurgen Contra Ricardo Salinas en Medio de Nuevas Revelaciones Judiciales y Fiscaleso
- Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2024 financial year
- SOILRES project launches to revive Europe’s soils and future-proof farming
- Josh Case, ancien cadre d’ENGIE Amérique du Nord, PDG de Photosol US Renewable Energy et consultant d’EDF Amérique du Nord, engage aujourd’hui toute son énergie dans la lutte contre la dépendance
- Bizzy startet den AI Sales Agent in Deutschland: ein intelligenter Agent zur Automatisierung der Vertriebspipeline
- Bizzy lance son agent commercial en France : un assistant intelligent qui automatise la prospection
- Bizzy lancia l’AI Sales Agent in Italia: un agente intelligente che automatizza la pipeline di vendita
- Bizzy lanceert AI Sales Agent in Nederland: slimme assistent automatiseert de sales pipeline
- Bizzy startet AI Sales Agent in Österreich: ein smarter Agent, der die Sales-Pipeline automatisiert
- Bizzy wprowadza AI Sales Agent w Polsce: inteligentny agent, który automatyzuje budowę lejka sprzedaży
- Bizzy lanza su AI Sales Agent en España: un agente inteligente que automatiza la generación del pipeline de ventas
- Bizzy launches AI Sales Agent in the UK: a smart assistant that automates sales pipeline generation
- As Sober.Buzz Community Explodes Its Growth Globally it is Announcing “Spreading the Good BUZZ” Podcast Hosted by Josh Case Debuting July 7th
- Digi Communications N.V. announces the OGMS resolutions and the availability of the approved 2024 Annual Report
- Escándalo Judicial en Aumento Alarma a la Opinión Pública: Suprema Corte de México Enfrenta Acusaciones de Favoritismo hacia el Aspirante a Magnate Ricardo Salinas Pliego
- Winz.io Named AskGamblers’ Best Casino 2025
- Kissflow Doubles Down on Germany as a Strategic Growth Market with New AI Features and Enterprise Focus
- Digi Communications N.V. announces Share transaction made by a Non-Executive Director of the Company with class B shares
- Salinas Pliego Intenta Frenar Investigaciones Financieras: UIF y Expertos en Corrupción Prenden Alarmas
- Digital integrity at risk: EU Initiative to strengthen the Right to be forgotten gains momentum
- Orden Propuesta De Arresto E Incautación Contra Ricardo Salinas En Corte De EE.UU
- Digi Communications N.V. announced that Serghei Bulgac, CEO and Executive Director, sold 15,000 class B shares of the company’s stock
- PFMcrypto lancia un sistema di ottimizzazione del reddito basato sull’intelligenza artificiale: il mining di Bitcoin non è mai stato così facile
- Azteca Comunicaciones en Quiebra en Colombia: ¿Un Presagio para Banco Azteca?
- OptiSigns anuncia su expansión Europea
- OptiSigns annonce son expansion européenne
- OptiSigns kündigt europäische Expansion an
- OptiSigns Announces European Expansion
- Digi Communications NV announces release of Q1 2025 financial report
- Banco Azteca y Ricardo Salinas Pliego: Nuevas Revelaciones Aumentan la Preocupación por Riesgos Legales y Financieros
- Digi Communications NV announces Investors Call for the presentation of the Q1 2025 Financial Results
- Digi Communications N.V. announces the publication of the 2024 Annual Financial Report and convocation of the Company’s general shareholders meeting for June 18, 2025, for the approval of, among others, the 2024 Annual Financial Report, available on the Company’s website
- La Suprema Corte Sanciona a Ricardo Salinas de Grupo Elektra por Obstrucción Legal
- Digi Communications N.V. announces the conclusion of an Incremental to the Senior Facilities Agreement dated 21 April 2023
- 5P Europe Foundation: New Initiative for African Children
- 28-Mar-2025: Digi Communications N.V. announces the conclusion of Facilities Agreements by companies within Digi Group
- Aeroluxe Expeditions Enters U.S. Market with High-Touch Private Jet Journeys—At a More Accessible Price ↗️
- SABIO GROUP TAKES IT’S ‘DISRUPT’ CX PROGRAMME ACROSS EUROPE
- EU must invest in high-quality journalism and fact-checking tools to stop disinformation
- ¿Está Banco Azteca al borde de la quiebra o de una intervención gubernamental? Preocupaciones crecientes sobre la inestabilidad financiera
- Netmore and Zenze Partner to Deploy LoRaWAN® Networks for Cargo and Asset Monitoring at Ports and Terminals Worldwide
- Rise Point Capital: Co-investing with Independent Sponsors to Unlock International Investment Opportunities
- Netmore Launches Metering-as-a-Service to Accelerate Smart Metering for Water and Gas Utilities
- Digi Communications N.V. announces that a share transaction was made by a Non-Executive Director of the Company with class B shares
- La Ballata del Trasimeno: Il Mediometraggio si Trasforma in Mini Serie
- Digi Communications NV Announces Availability of 2024 Preliminary Financial Report
- Digi Communications N.V. announces the recent evolution and performance of the Company’s subsidiary in Spain
- BevZero Equipment Sales and Distribution Enhances Dealcoholization Capabilities with New ClearAlc 300 l/h Demonstration Unit in Spain Facility
- Digi Communications NV announces Investors Call for the presentation of the 2024 Preliminary Financial Results
- Reuters webinar: Omnibus regulation Reuters post-analysis
- Patients as Partners® Europe Launches the 9th Annual Event with 2025 Keynotes, Featured Speakers and Topics
- eVTOLUTION: Pioneering the Future of Urban Air Mobility
- Reuters webinar: Effective Sustainability Data Governance
- Las acusaciones de fraude contra Ricardo Salinas no son nuevas: una perspectiva histórica sobre los problemas legales del multimillonario
- Digi Communications N.V. Announces the release of the Financial Calendar for 2025
- USA Court Lambasts Ricardo Salinas Pliego For Contempt Of Court Order
- 3D Electronics: A New Frontier of Product Differentiation, Thinks IDTechEx
- Ringier Axel Springer Polska Faces Lawsuit for Over PLN 54 million
- Digi Communications N.V. announces the availability of the report on corporate income tax information for the financial year ending December 31, 2023
- Unlocking the Multi-Million-Dollar Opportunities in Quantum Computing
- Digi Communications N.V. Announces the Conclusion of Facilities Agreements by Companies within Digi Group
- The Hidden Gem of Deep Plane Facelifts
- KAZANU: Redefining Naturist Hospitality in Saint Martin ↗️
- New IDTechEx Report Predicts Regulatory Shifts Will Transform the Electric Light Commercial Vehicle Market
- Almost 1 in 4 Planes Sold in 2045 to be Battery Electric, Finds IDTechEx Sustainable Aviation Market Report
- Digi Communications N.V. announces the release of Q3 2024 financial results
- Digi Communications NV announces Investors Call for the presentation of the Q3 2024 Financial Results
- Pilot and Electriq Global announce collaboration to explore deployment of proprietary hydrogen transport, storage and power generation technology
- Digi Communications N.V. announces the conclusion of a Memorandum of Understanding by its subsidiary in Romania
- Digi Communications N.V. announces that the Company’s Portuguese subsidiary finalised the transaction with LORCA JVCO Limited
- Digi Communications N.V. announces that the Portuguese Competition Authority has granted clearance for the share purchase agreement concluded by the Company’s subsidiary in Portugal
- OMRON Healthcare introduceert nieuwe bloeddrukmeters met AI-aangedreven AFib-detectietechnologie; lancering in Europa september 2024
- OMRON Healthcare dévoile de nouveaux tensiomètres dotés d’une technologie de détection de la fibrillation auriculaire alimentée par l’IA, lancés en Europe en septembre 2024
- OMRON Healthcare presenta i nuovi misuratori della pressione sanguigna con tecnologia di rilevamento della fibrillazione atriale (AFib) basata sull’IA, in arrivo in Europa a settembre 2024
- OMRON Healthcare presenta los nuevos tensiómetros con tecnología de detección de fibrilación auricular (FA) e inteligencia artificial (IA), que se lanzarán en Europa en septiembre de 2024
- Alegerile din Moldova din 2024: O Bătălie pentru Democrație Împotriva Dezinformării
- Northcrest Developments launches design competition to reimagine 2-km former airport Runway into a vibrant pedestrianized corridor, shaping a new era of placemaking on an international scale
- The Road to Sustainable Electric Motors for EVs: IDTechEx Analyzes Key Factors
- Infrared Technology Breakthroughs Paving the Way for a US$500 Million Market, Says IDTechEx Report
- MegaFair Revolutionizes the iGaming Industry with Skill-Based Games
- European Commission Evaluates Poland’s Media Adherence to the Right to be Forgotten
- Global Race for Autonomous Trucks: Europe a Critical Region Transport Transformation
- Digi Communications N.V. confirms the full redemption of €450,000,000 Senior Secured Notes
- AT&T Obtiene Sentencia Contra Grupo Salinas Telecom, Propiedad de Ricardo Salinas, Sus Abogados se Retiran Mientras Él Mueve Activos Fuera de EE.UU. para Evitar Pagar la Sentencia
- Global Outlook for the Challenging Autonomous Bus and Roboshuttle Markets
- Evolving Brain-Computer Interface Market More Than Just Elon Musk’s Neuralink, Reports IDTechEx
- Latin Trails Wraps Up a Successful 3rd Quarter with Prestigious LATA Sustainability Award and Expands Conservation Initiatives ↗️
- Astor Asset Management 3 Ltd leitet Untersuchung für potenzielle Sammelklage gegen Ricardo Benjamín Salinas Pliego von Grupo ELEKTRA wegen Marktmanipulation und Wertpapierbetrug ein
- Digi Communications N.V. announces that the Company’s Romanian subsidiary exercised its right to redeem the Senior Secured Notes due in 2025 in principal amount of €450,000,000
- Astor Asset Management 3 Ltd Inicia Investigación de Demanda Colectiva Contra Ricardo Benjamín Salinas Pliego de Grupo ELEKTRA por Manipulación de Acciones y Fraude en Valores
- Astor Asset Management 3 Ltd Initiating Class Action Lawsuit Inquiry Against Ricardo Benjamín Salinas Pliego of Grupo ELEKTRA for Stock Manipulation & Securities Fraud
- Digi Communications N.V. announced that its Spanish subsidiary, Digi Spain Telecom S.L.U., has completed the first stage of selling a Fibre-to-the-Home (FTTH) network in 12 Spanish provinces
- Natural Cotton Color lancia la collezione "Calunga" a Milano
- Astor Asset Management 3 Ltd: Salinas Pliego Incumple Préstamo de $110 Millones USD y Viola Regulaciones Mexicanas
- Astor Asset Management 3 Ltd: Salinas Pliego Verstößt gegen Darlehensvertrag über 110 Mio. USD und Mexikanische Wertpapiergesetze
- ChargeEuropa zamyka rundę finansowania, której przewodził fundusz Shift4Good tym samym dokonując historycznej francuskiej inwestycji w polski sektor elektromobilności
- Strengthening EU Protections: Robert Szustkowski calls for safeguarding EU citizens’ rights to dignity
- Digi Communications NV announces the release of H1 2024 Financial Results
- Digi Communications N.V. announces that conditional stock options were granted to a director of the Company’s Romanian Subsidiary
- Digi Communications N.V. announces Investors Call for the presentation of the H1 2024 Financial Results
- Digi Communications N.V. announces the conclusion of a share purchase agreement by its subsidiary in Portugal
- Digi Communications N.V. Announces Rating Assigned by Fitch Ratings to Digi Communications N.V.
- Digi Communications N.V. announces significant agreements concluded by the Company’s subsidiaries in Spain
- SGW Global Appoints Telcomdis as the Official European Distributor for Motorola Nursery and Motorola Sound Products
- Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2023 financial year
- Digi Communications N.V. announces the exercise of conditional share options by the executive directors of the Company, for the year 2023, as approved by the Company’s Ordinary General Shareholders’ Meetings from 18th May 2021 and 28th December 2022
- Digi Communications N.V. announces the granting of conditional stock options to Executive Directors of the Company based on the general shareholders’ meeting approval from 25 June 2024
- Digi Communications N.V. announces the OGMS resolutions and the availability of the approved 2023 Annual Report
- Czech Composer Tatiana Mikova Presents Her String Quartet ‘In Modo Lidico’ at Carnegie Hall
- SWIFTT: A Copernicus-based forest management tool to map, mitigate, and prevent the main threats to EU forests
- WickedBet Unveils Exciting Euro 2024 Promotion with Boosted Odds
- Museum of Unrest: a new space for activism, art and design
- Digi Communications N.V. announces the conclusion of a Senior Facility Agreement by companies within Digi Group
- Digi Communications N.V. announces the agreements concluded by Digi Romania (formerly named RCS & RDS S.A.), the Romanian subsidiary of the Company
- Green Light for Henri Hotel, Restaurants and Shops in the “Alter Fischereihafen” (Old Fishing Port) in Cuxhaven, opening Summer 2026
- Digi Communications N.V. reports consolidated revenues and other income of EUR 447 million, adjusted EBITDA (excluding IFRS 16) of EUR 140 million for Q1 2024
- Digi Communications announces the conclusion of Facilities Agreements by companies from Digi Group
- Digi Communications N.V. Announces the convocation of the Company’s general shareholders meeting for 25 June 2024 for the approval of, among others, the 2023 Annual Report
- Digi Communications NV announces Investors Call for the presentation of the Q1 2024 Financial Results
- Digi Communications intends to propose to shareholders the distribution of dividends for the fiscal year 2023 at the upcoming General Meeting of Shareholders, which shall take place in June 2024
- Digi Communications N.V. announces the availability of the Romanian version of the 2023 Annual Report
- Digi Communications N.V. announces the availability of the 2023 Annual Report
- International Airlines Group adopts Airline Economics by Skailark ↗️
- BevZero Spain Enhances Sustainability Efforts with Installation of Solar Panels at Production Facility
- Digi Communications N.V. announces share transaction made by an Executive Director of the Company with class B shares
- BevZero South Africa Achieves FSSC 22000 Food Safety Certification
- Digi Communications N.V.: Digi Spain Enters Agreement to Sell FTTH Network to International Investors for Up to EUR 750 Million
- Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics
- driveMybox continues its international expansion: Hungary as a new strategic location
- Monesave introduces Socialised budgeting: Meet the app quietly revolutionising how users budget
- Digi Communications NV announces the release of the 2023 Preliminary Financial Results
- Digi Communications NV announces Investors Call for the presentation of the 2023 Preliminary Financial Results
- Lensa, един от най-ценените търговци на оптика в Румъния, пристига в България. Първият шоурум е открит в София
- Criando o futuro: desenvolvimento da AENO no mercado de consumo em Portugal
- Digi Communications N.V. Announces the release of the Financial Calendar for 2024
- Customer Data Platform Industry Attracts New Participants: CDP Institute Report
- eCarsTrade annonce Dirk Van Roost au poste de Directeur Administratif et Financier: une décision stratégique pour la croissance à venir
- BevZero Announces Strategic Partnership with TOMSA Desil to Distribute equipment for sustainability in the wine industry, as well as the development of Next-Gen Dealcoholization technology
- Editor's pick archive....